公开(公告)号：US20220243222A1

公开(公告)日：2022-08-04

申请号：US17609303

申请日：2020-05-04

Applicant: AMGEN INC.

Inventor： Pavan Ghattyvenkatakrishna ,  Hedieh Barkhordarian ,  Kristine Marie Daris ,  Charilyn Tejamo

IPC: C12N15/85 ,  C12N9/00 ,  C12N15/62 ,  C07K16/06

Abstract: Inventions disclosed herein relates to vectors and expression systems for producing heteromeric recombinant proteins such as monoclonal antibodies. Vectors and expression systems disclosed herein are based on the finding that the selectable marker glutamine synthetase can be divided into two fragments at selected amino acid positions of the glutamine synthetase polypeptide, and the two fragments can internet and/or associate to form a monomer and then a functional multimeric glutamine synthetase protein. Z

公开(公告)号：US11192952B2

公开(公告)日：2021-12-07

申请号：US16608375

申请日：2018-04-27

Applicant: AMGEN INC.

Inventor： Stephen Robert Brych ,  Lyanne M. Wong ,  Jaymille Fallon ,  Monica Michelle Goss ,  Jian Hua Gu ,  Pavan Ghattyvenkatakrishna

IPC: C07K16/28 ,  A61K39/00

Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.

公开(公告)号：US20200332000A1

公开(公告)日：2020-10-22

申请号：US16482603

申请日：2018-02-02

Applicant: AMGEN RESEARCH (MUNICH) GMBH ,  AMGEN INC.

Inventor： Arnold Mcauley ,  Pavan Ghattyvenkatakrishna ,  Jeff Abel ,  Joon Huh ,  Cornelius Pompe ,  Sekhar Kanapuram ,  Michael Treuheit ,  Bharadwaj Jagannathan

IPC: C07K16/28 ,  A61K47/26

Abstract: The present disclosure provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.

公开(公告)号：US12103979B2

公开(公告)日：2024-10-01

申请号：US16607673

申请日：2018-04-27

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish Agrawal ,  Pavan Ghattyvenkatakrishna ,  Sekhar Kanapuram ,  Christopher James Sloey

IPC: A61K39/395 ,  A61K9/08 ,  A61K9/19 ,  A61K31/198 ,  A61K31/401 ,  A61K31/4172 ,  A61K38/05 ,  A61K47/18 ,  A61K47/26 ,  C07K5/06 ,  C07K16/18 ,  C07K16/40

CPC classification number: C07K16/40 ,  A61K9/08 ,  A61K9/19 ,  A61K31/198 ,  A61K31/401 ,  A61K31/4172 ,  A61K38/05 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/26 ,  C07K5/06 ,  C07K16/18

Abstract: Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.

公开(公告)号：US20230406929A1

公开(公告)日：2023-12-21

申请号：US18251120

申请日：2021-11-08

Applicant: AMGEN INC. ,  AMGEN RESEARCH (MUNICH)

Inventor： Doris Rau ,  Tobias Raum ,  Partrick Hoffmann ,  Markus Muenz ,  Matthias Klinger ,  Virginie Naegele ,  Lisa Winkel ,  Pavan Ghattyvenkatakrishna ,  Joon Hoi Huh ,  Arnold McAuley ,  Sekhar Kanapuram

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  C07K16/2875 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2317/92

Abstract: The invention relates to a polypeptide or polypeptide construct comprising: a binding domain binding to an extracellular epitope of the human CD3s chain comprising or consisting of a VH region and a VL region, wherein i) the VH region comprises: a CDR-H1 sequence of X1YAX2N, where X1 is K, V, S, G, R, T, or I; and X2 is M or I; a CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2, where X1 is S or Q; and X2 is D, G, K, S, or E; and a CDR-H3 sequence of HX1NFGNSYX2SX3X4AY, where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W or F; and X4 is W, F or Y; and ii) wherein the VL region comprises: a CDR-L1 sequence of X1 SSTGAVTX2X3X4YX5N, where X1 is G, R, or A; X2 is S or T; X3 is G or S; X4 is N or Y and X5 is P or A; a CDR-L2 sequence of X1TX2X3X4X5X6; where X1 is G or A; X2 is K, D, or N; X3 is F, M or K; X4 is L or R; X5 is A, P, or V; and X6 is P or S; and a CDR-L3 sequence of X1LWYSNX2VW, where X1 is V, A, or T; and X2 is R or L; and iii) wherein one or more of CDR sequences of the VH region of i) and/or of the VL region of ii) comprise one amino acid substitution or a combination thereof selected from X24V and X24F in CDR-H1; D15, and X116A in CDR-H2; H1, X12E, F4, and N6 in CDR-H3; and X11L and W3 in CDR-L3. The invention also relates to a polynucleotide encoding the polypeptide or polypeptide construct of the invention, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or with said vector. Moreover, the invention also provides for a process for the production of said polypeptide or polypeptide construct and a pharmaceutical composition comprising said polypeptide or polypeptide construct of the invention. Furthermore, the invention relates to medical uses of said polypeptide or polypeptide construct and kits comprising said polypeptide or polypeptide construct.

公开(公告)号：US20230203198A1

公开(公告)日：2023-06-29

申请号：US17928577

申请日：2021-06-03

Applicant: AMGEN INC.

Inventor： Pavan Ghattyvenkatakrishna ,  Brendan Amer

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/468 ,  C07K16/2809 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  A61K45/06 ,  A61K39/3955 ,  C07K2317/31 ,  C07K2319/02 ,  C07K2317/622

Abstract: New formats of bispecific binding constructs are described that bind to a target antigen and to a CD3 molecule on an effector cell, as well as their methods of making Additionally, uses in therapeutic indications are also described.